TG Therapeutics
TGTX
222 hedge funds and large institutions have $3.21B invested in TG Therapeutics in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 79 increasing their positions, 77 reducing their positions, and 46 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 77
0.53% less ownership
Funds ownership: 68.03% → 67.5% (-0.53%)
6% less funds holding
Funds holding: 237 → 222 (-15)
14% less capital invested
Capital invested by funds: $3.73B → $3.21B (-$517M)
15% less call options, than puts
Call options by funds: $71.6M | Put options by funds: $83.9M
30% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 46
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$24.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$23.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$20.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$82.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$46.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$19.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.2M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$11.8M |
TGTX Hedge Fund Activity: Q3 2021 in Review
222 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2021, worth a combined $3.21B — down 14% from $3.73B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of TGTX and 32 opened new positions — a net loss of 14 holders — while 77 trimmed existing stakes and 79 added.
The largest buyer was Group One Trading, adding an estimated $24.6M. The largest seller was Wellington Management Group, cutting an estimated $82.7M.
- 222 institutional investors held TG Therapeutics (TGTX) as of Q3 2021, down from 237 in Q2 2021.
- Funds reported $3.21B of TG Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
- 32 funds opened new TG Therapeutics positions in Q3 2021 and 46 closed out, a net change of -14 holders.
- The largest TG Therapeutics buyer in Q3 2021 was Group One Trading, an estimated $24.6M added.
- The largest TG Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $82.7M sold.
Based on aggregated 13F filings for Q3 2021.